{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:08:46Z","timestamp":1794485326529,"version":"4.9.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.vaccine.2025.126840","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T08:50:41Z","timestamp":1739177441000},"page":"126840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Microarray patches likely to reduce the operational costs of immunization: A Monte Carlo simulation study"],"prefix":"10.1016","volume":"50","author":[{"given":"Brittany","family":"Hagedorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Scarna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fayad","family":"El Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.126840_bb0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1208\/s12249-022-02250-8","article-title":"Microneedle-based vaccine delivery: review of an emerging technology","volume":"23","author":"Mansoor","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.vaccine.2025.126840_bb0010","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1016\/j.vaccine.2015.01.089","article-title":"Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque","volume":"33","author":"Edens","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126840_bb0015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2019.08.039","article-title":"Skin delivery of trivalent Sabin inactivated poliovirus vaccine using dissolvable microneedle patches induces neutralizing antibodies","volume":"311\u2013312","author":"Donadei","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2025.126840_bb0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41541-022-00443-7","article-title":"Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine","volume":"7","author":"Moon","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2025.126840_bb0025","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.vaccine.2014.01.076","article-title":"Microneedle patches: usability and acceptability for self-vaccination against influenza","volume":"32","author":"Norman","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126840_bb0030","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0140-6736(17)30575-5","article-title":"The safety, immunogenicity and acceptability of inactivated influenza vaccine delivered by microneedle patch: a randomized, partially blind, placebo-controlled phase 1 trial HHS public access","volume":"390","author":"Rouphael","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.126840_bb0035","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40268-016-0144-x","article-title":"Assessing the potential cost-effectiveness of microneedle patches in childhood measles vaccination programs: the case for further Research and Development","volume":"16","author":"Adhikari","year":"2016","journal-title":"Drugs R D"},{"key":"10.1016\/j.vaccine.2025.126840_bb0040","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.ijbiomac.2019.04.163","article-title":"A compendium of current developments on polysaccharide and protein-based microneedles","volume":"136","author":"Fonseca","year":"2019","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.vaccine.2025.126840_bb0045","first-page":"12","article-title":"Development of the H3N2 influenza microneedle vaccine for cross-protection against antigenic variants","author":"Shin","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.126840_bb0050","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1016\/j.vaccine.2022.07.013","article-title":"Skin-patch delivered subunit vaccine induces broadly neutralising antibodies against SARS-CoV-2 variants of concern","volume":"40","author":"McMillan","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126840_bb0055","first-page":"14","article-title":"Skin vaccination with Ebola virus glycoprotein using a Polyphosphazene-based microneedle patch protects mice against lethal challenge","author":"Romanyuk","year":"2022","journal-title":"J Funct Biomater"},{"key":"10.1016\/j.vaccine.2025.126840_bb0060","first-page":"17","article-title":"Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: results from a randomized, controlled phase I clinical trial","author":"Forster","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2025.126840_bb0065","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coviro.2020.05.005","article-title":"A microneedle patch for measles and rubella vaccination: a game changer for achieving elimination","volume":"41","author":"Prausnitz","year":"2020","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2025.126840_bb0070","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s13346-021-01076-4","article-title":"Manufacturing readiness assessment for evaluation of the microneedle array patch industry: an exploration of barriers to full-scale manufacturing","volume":"12","author":"Creelman","year":"2022","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.vaccine.2025.126840_bb0075","series-title":"Measles-rubella microarray patch (MR\u2013MAP) target product profile. Geneva","author":"WHO","year":"2019"},{"key":"10.1016\/j.vaccine.2025.126840_bb0080","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1016\/j.vaccine.2017.03.081","article-title":"Economic impact of thermostable vaccines","volume":"35","author":"Lee","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126840_bb0085","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.vaccine.2018.12.008","article-title":"The potential effects of introducing microneedle patch vaccines into routine vaccine supply chains","volume":"37","author":"Wedlock","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126840_bb0090","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.vaccine.2016.01.001","article-title":"Can thermostable vaccines help address cold-chain challenges? Results from stakeholder interviews in six low- and middle-income countries","volume":"34","author":"Kristensen","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126840_bb0095","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/15321819.2014.920713","article-title":"Measles vaccine potency and sero-conversion rates among infants receiving measles immunization in Ilorin, Kwara state","volume":"36","author":"Fowotade","year":"2015","journal-title":"Nigeria J Immunoassay Immunochem"},{"key":"10.1016\/j.vaccine.2025.126840_bb0100","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1016\/j.vaccine.2015.02.074","article-title":"A microneedle patch containing measles vaccine is immunogenic in non-human primates","volume":"33","author":"Edens","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126840_bb0105","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1017\/S1368980017000684","article-title":"Determinants of successful vitamin a supplementation coverage among children aged 6-59 months in thirteen sub-Saharan African countries","volume":"20","author":"Janmohamed","year":"2017","journal-title":"Public Health Nutr"},{"key":"10.1016\/j.vaccine.2025.126840_bb0110","series-title":"Implementation, coverage and equity of large-scale door-to-door delivery of seasonal malaria chemoprevention (SMC) to children under 10 in Senegal","author":"B\u00e2","year":"2018"},{"key":"10.1016\/j.vaccine.2025.126840_bb0115","series-title":"Strategies to improve treatment coverage in community-based public health programs: A systematic review of the literature","author":"Deardorff","year":"2018"},{"key":"10.1016\/j.vaccine.2025.126840_bb0120","series-title":"Ultra-low temperature (ULT) storage and transport for vaccines","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.vaccine.2025.126840_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2022.100184","article-title":"The status of refrigeration solutions for last mile vaccine delivery in low-income settings","volume":"11","author":"Cattin","year":"2022","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2025.126840_bb0130","first-page":"12","article-title":"An application of an initial full value of vaccine assessment methodology to measles-rubella MAPs for use in low- and middle-income countries","author":"Ko","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.126840_bb0135","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1016\/j.vaccine.2012.09.062","article-title":"Measles vaccination using a microneedle patch","volume":"31","author":"Edens","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126840_bb0140","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1016\/j.vaccine.2009.04.005","article-title":"Pediatric vaccination errors: application of the \u201c5 rights\u201d framework to a national error reporting database","volume":"27","author":"Bundy","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126840_bb0145","series-title":"Comparative analysis of cost of biomedical waste management in rural India","first-page":"11","volume":"4","author":"Article","year":"2016"},{"key":"10.1016\/j.vaccine.2025.126840_bb0150","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.126840_bb0155","series-title":"Health-care waste n.d","author":"World Health Organization","year":"2023"},{"key":"10.1016\/j.vaccine.2025.126840_bb0160","series-title":"Sharps injuries: assessing the burden of disease from sharps injuries to health-care workers at national and local levels. Geneva","author":"Rapiti","year":"2005"},{"key":"10.1016\/j.vaccine.2025.126840_bb0165","series-title":"Prophylactic HPV vaccine microarray patch: target product profile. Seattle","author":"PATH","year":"2020"},{"key":"10.1016\/j.vaccine.2025.126840_bb0170","series-title":"Rabies vaccine microarray patch: target product profile. Seattle","author":"PATH","year":"2020"},{"key":"10.1016\/j.vaccine.2025.126840_bb0175","series-title":"World health organization, bill & melinda gates foundation, PATH, unicef. The vips prioritisation process: methodology and outcomes. Geneva","author":"Gavi","year":"2020"},{"key":"10.1016\/j.vaccine.2025.126840_bb0180","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1016\/j.vaccine.2020.07.012","article-title":"The effects of switching from 10 to 5-dose vials of MR vaccine on vaccination coverage and wastage: a mixed-method study in Zambia","volume":"38","author":"Krudwig","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126840_bb0185","series-title":"Revising global indicative wastage rates: a WHO initiative for better planning and forecasting of vaccine supply needs","author":"World Health Organization","year":"2019"},{"key":"10.1016\/j.vaccine.2025.126840_bb0190","series-title":"Introducing the measles and measles-rubella (mr) vaccine five-dose vial presentations facts sheet \u2013 february 2019","first-page":"1","author":"Sheet","year":"2019"},{"key":"10.1016\/j.vaccine.2025.126840_bb0195","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1186\/s12889-018-5762-5","article-title":"Vaccine wastage in the Gambia: a prospective observational study","volume":"18","author":"Usuf","year":"2018","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2025.126840_bb0200","doi-asserted-by":"crossref","first-page":"6751","DOI":"10.1016\/j.vaccine.2017.09.082","article-title":"Vaccine wastage in Nigeria: an assessment of wastage rates and related vaccinator knowledge, attitudes and practices","volume":"35","author":"Wallace","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126840_bb0205","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2471\/BLT.13.119974","article-title":"Frequent exposure to suboptimal temperatures in vaccine cold-chain system in India: results of temperature monitoring in 10 states","volume":"91","author":"Murhekar","year":"2013","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2025.126840_bb0210","first-page":"205","article-title":"Strengthening evidence-based planning of integrated health service delivery through local measures of health intervention delivery times","author":"Wallace","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126840_bb0215","series-title":"Pentavalent vaccine in the uniject\u2122 injection system: a time and motion study. Seattle","author":"PATH","year":"2014"},{"key":"10.1016\/j.vaccine.2025.126840_bb0220","series-title":"Evaluation of the self-administration potential of high-density microarray patches to human skin: A preliminary study","author":"Baker","year":"2023"},{"key":"10.1016\/j.vaccine.2025.126840_bb0225","series-title":"Best practices in microplanning for polio eradication","author":"WHO, GPEI","year":"2019"},{"key":"10.1016\/j.vaccine.2025.126840_bb0230","first-page":"1","article-title":"Planning and implementing high quality supplementary immunization activities for measles-rubella and other injectable vaccines FIELD GUIDE. World health","author":"WHO","year":"2012","journal-title":"Organization"},{"key":"10.1016\/j.vaccine.2025.126840_bb0235","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1016\/j.vaccine.2019.08.049","article-title":"The cost saving opportunity of introducing a card review into measles-containing vaccination campaigns","volume":"37","author":"Hagedorn","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126840_bb0240","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.wasman.2012.09.021","article-title":"Applications of life cycle assessment and cost analysis in health care waste management","volume":"33","author":"Soares","year":"2013","journal-title":"Waste Manag"},{"key":"10.1016\/j.vaccine.2025.126840_bb0245","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1016\/j.vaccine.2015.07.033","article-title":"Landscaping the structures of GAVI country vaccine supply chains and testing the effects of radical redesign","volume":"33","author":"Lee","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126840_bb0250","series-title":"Supply catalogue. bandage, adhesive, 3.0 cm, box\/100 S0001407","author":"UNICEF","year":"2024"},{"key":"10.1016\/j.vaccine.2025.126840_bb0255","first-page":"11","article-title":"Community health workers as vaccinators: a rapid review of the global landscape, 2000-2021","author":"Gibson","year":"2023","journal-title":"Glob Health Sci Pract"},{"key":"10.1016\/j.vaccine.2025.126840_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253518","article-title":"Analysis of policy interventions to attract and retain nurse midwives in rural areas of Malawi: a discrete choice experiment","volume":"16","author":"Berman","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.126840_bb0265","first-page":"11","article-title":"Community health workers as vaccinators: a rapid review of the global landscape, 2000-2021 key findings","author":"Gibson","year":"2023","journal-title":"Glob Health Sci Pract"},{"key":"10.1016\/j.vaccine.2025.126840_bb0270","series-title":"Measles-rubella microarray patch (MR-MAP) target product profile","author":"WHO, UNICEF","year":"2019"},{"key":"10.1016\/j.vaccine.2025.126840_bb0275","doi-asserted-by":"crossref","first-page":"7208","DOI":"10.1016\/j.vaccine.2021.07.091","article-title":"Strategies for vaccine-product innovation: creating an enabling environment for product development to uptake in low- and middle-income countries","volume":"39","author":"Giersing","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126840_bb0280","series-title":"Public summary of the VIPS alliance action plan","author":"Vaccine Microarray Patches (MAPs)","year":"2024"},{"key":"10.1016\/j.vaccine.2025.126840_bb0285","series-title":"India\u2019s medical waste growing at 7% annually: ASSOCHAM. Times of India","author":"Shenoy","year":"2018"},{"key":"10.1016\/j.vaccine.2025.126840_bb0290","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/j.1365-3156.2009.02386.x","article-title":"Health care waste management: a neglected and growing public health problem worldwide","volume":"14","author":"Harhay","year":"2009","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.vaccine.2025.126840_bb0295","first-page":"182","article-title":"Healthcare waste treatment technologies and health impacts of","volume":"11","author":"Aydin","year":"2016","journal-title":"Waste Manag"},{"key":"10.1016\/j.vaccine.2025.126840_bb0300","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/jpc.14752","article-title":"Lessons from the tragic measles outbreak in Samoa","volume":"56","author":"Isaacs","year":"2020","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.vaccine.2025.126840_bb0305","first-page":"37","article-title":"Modeling the economic impact of different vial-opening thresholds for measles-containing vaccines","author":"Wedlock","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126840_bb0310","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00002018-199819060-00002","article-title":"Measles vaccines. A review of adverse events","volume":"19","author":"Duclos","year":"1998","journal-title":"Drug Saf"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25001379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25001379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T15:29:53Z","timestamp":1741793393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25001379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":62,"alternative-id":["S0264410X25001379"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126840","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microarray patches likely to reduce the operational costs of immunization: A Monte Carlo simulation study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126840"}}